Clinical Observation of Peginterferon α-2a Combined with Adefovir Dipivioxil Antivirus Treatment in Chronic Hepatitis B Patients with Low ALT Level

Objective: To investigate the effect of antivirus treatment in chronic hepatitis B(CHB) patients with low ALT level. Method: 156 CHB patients with low ALT level were equally randomly divided into 4 groups: the HBe Ag(+) treatment group(group A)for 42 cases and the control group(group B)for 40 cases; the HBe Ag(-) treatmentgroup( group C)for 36 cases and the corresponding control group( group D)for 38 cases. The patients in the HBe Ag(+) or HBe Ag(-) treatment group were respectively given peginterferon α-2a(180 μg) once a week,after 24 weeks, these patients were added with Adefovir dipivioxil(10 mg) once a day,after 48 weeks,Peginterferon α-2a was stoped and Adefovir dipivioxil was given continually to the patients.Two control groups were respectively given Adefovir dipivioxil(10 mg, once a day), the stopping standand of antiviral drugs was according to the guideline of prevention and treatment for CHB in 2005,China.Result: The HBV-DNA conversion rates,HBe Ag conversion rates and the relapsing rate after stop of antivirus drugs for 24 weeks in group A were all significantly different from the group B(P0.05); the HBVDNA conversion rates after treatment for 24,48 and 72 weeks were not different between group C and group D(P0.05), however, the relapsing rate after stop of antivirus drugs for 24 weeks in group C was significantly different from the group D(P0.05).Conclusion:Peginterferon α-2a combined with Adefovir dipivioxil treatment may enhance therapeutic effect and lower relapsing rate in HBe Ag(+) CHB patients with low ALT level, furthermore, it can decrease relapsing rate for HBe Ag(-) CHB patients.